JPWO2020086745A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020086745A5 JPWO2020086745A5 JP2021522078A JP2021522078A JPWO2020086745A5 JP WO2020086745 A5 JPWO2020086745 A5 JP WO2020086745A5 JP 2021522078 A JP2021522078 A JP 2021522078A JP 2021522078 A JP2021522078 A JP 2021522078A JP WO2020086745 A5 JPWO2020086745 A5 JP WO2020086745A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- fragment
- domain
- receptor
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims description 248
- 239000012634 fragment Substances 0.000 claims description 141
- 239000003446 ligand Substances 0.000 claims description 61
- 108020003175 receptors Proteins 0.000 claims description 55
- 102000005962 receptors Human genes 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 43
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims description 41
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims description 41
- 235000001014 amino acid Nutrition 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims description 13
- 235000004279 alanine Nutrition 0.000 claims description 12
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 6
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 6
- 102000048776 human CD274 Human genes 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000010170 Death domains Human genes 0.000 claims description 4
- 108050001718 Death domains Proteins 0.000 claims description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 4
- 102100030712 Immunoglobulin-like domain-containing receptor 2 Human genes 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000023732 binding proteins Human genes 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 230000009149 molecular binding Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 101710082281 Immunoglobulin-like domain-containing receptor 2 Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000000989 Complement System Proteins Human genes 0.000 claims description 2
- 108010069112 Complement System Proteins Proteins 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 230000029142 excretion Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101001010614 Homo sapiens Immunoglobulin-like domain-containing receptor 2 Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101710154541 Modulator protein Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749429P | 2018-10-23 | 2018-10-23 | |
| US62/749,429 | 2018-10-23 | ||
| PCT/US2019/057702 WO2020086745A1 (en) | 2018-10-23 | 2019-10-23 | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505663A JP2022505663A (ja) | 2022-01-14 |
| JP2022505663A5 JP2022505663A5 (https=) | 2022-10-28 |
| JPWO2020086745A5 true JPWO2020086745A5 (https=) | 2022-10-28 |
Family
ID=70331240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522078A Pending JP2022505663A (ja) | 2018-10-23 | 2019-10-23 | ＩｇＭ－Ｆｃベース及びＩｇＡ－Ｆｃベースの多価結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210380701A1 (https=) |
| EP (1) | EP3870223A4 (https=) |
| JP (1) | JP2022505663A (https=) |
| KR (1) | KR20210083260A (https=) |
| CN (1) | CN112839677A (https=) |
| AU (1) | AU2019368289A1 (https=) |
| CA (1) | CA3113268A1 (https=) |
| IL (1) | IL281901A (https=) |
| MX (1) | MX2021004660A (https=) |
| SG (1) | SG11202103720XA (https=) |
| WO (1) | WO2020086745A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017512208A (ja) | 2014-02-10 | 2017-05-18 | アイジーエム バイオサイエンス， インコーポレイテッド | ＩｇＡ多重特異性結合分子 |
| IL292311A (en) | 2014-04-03 | 2022-06-01 | Igm Biosciences Inc | J-chain qualified |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| KR102357312B1 (ko) | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| WO2016168758A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| EP3824903A1 (en) | 2015-09-30 | 2021-05-26 | IGM Biosciences Inc. | Binding molecules with modified j-chain |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| JP6979971B2 (ja) | 2016-05-09 | 2021-12-15 | アイジーエム バイオサイエンシズ インコーポレイテッド | 抗ｐｄ−ｌ１抗体 |
| US11401337B2 (en) | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| MX2022001934A (es) | 2019-08-15 | 2022-03-11 | Igm Biosciences Inc | Moleculas de union multimericas inmunoestimuladoras. |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| BR112022021392A2 (pt) * | 2020-04-22 | 2022-12-06 | Igm Biosciences Inc | Moléculas de ligação multiméricas de agonista de pd-1 |
| CN116813759B (zh) * | 2022-03-21 | 2025-11-28 | 中国科学院微生物研究所 | 纳米抗体r14的构建体及其应用 |
| WO2023196995A1 (en) * | 2022-04-07 | 2023-10-12 | Repertoire Immune Medicines, Inc. | T cell receptor multimers and uses thereof |
| CA3248964A1 (en) * | 2022-04-15 | 2025-07-10 | Imbiologics Corp. | Fusion protein platform with an improved half-life |
| WO2024073700A2 (en) * | 2022-09-30 | 2024-04-04 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0975355A2 (en) * | 1996-06-14 | 2000-02-02 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
| DK2604693T3 (en) * | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
| JP6205363B2 (ja) * | 2011-09-26 | 2017-09-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | ハイブリッド定常領域 |
| JP2017512208A (ja) * | 2014-02-10 | 2017-05-18 | アイジーエム バイオサイエンス， インコーポレイテッド | ＩｇＡ多重特異性結合分子 |
| PT3247728T (pt) * | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| KR102357312B1 (ko) * | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| WO2016154593A1 (en) * | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2017300647A1 (en) * | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric GITR binding molecules and uses thereof |
| JP2019530640A (ja) * | 2016-07-20 | 2019-10-24 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体ｏｘ４０結合分子及びその使用 |
| US11401337B2 (en) * | 2017-04-07 | 2022-08-02 | Igm Biosciences, Inc. | Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function |
-
2019
- 2019-10-23 KR KR1020217011641A patent/KR20210083260A/ko not_active Ceased
- 2019-10-23 EP EP19875608.2A patent/EP3870223A4/en not_active Withdrawn
- 2019-10-23 CA CA3113268A patent/CA3113268A1/en active Pending
- 2019-10-23 MX MX2021004660A patent/MX2021004660A/es unknown
- 2019-10-23 SG SG11202103720XA patent/SG11202103720XA/en unknown
- 2019-10-23 US US17/287,828 patent/US20210380701A1/en not_active Abandoned
- 2019-10-23 WO PCT/US2019/057702 patent/WO2020086745A1/en not_active Ceased
- 2019-10-23 AU AU2019368289A patent/AU2019368289A1/en not_active Abandoned
- 2019-10-23 CN CN201980067597.2A patent/CN112839677A/zh active Pending
- 2019-10-23 JP JP2021522078A patent/JP2022505663A/ja active Pending
-
2021
- 2021-03-30 IL IL281901A patent/IL281901A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020086745A5 (https=) | ||
| KR102483755B1 (ko) | 키메라 폴리펩티드 및 그의 용도 | |
| US20210380701A1 (en) | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES | |
| CN106456733B (zh) | Syntac多肽及其用途 | |
| CA3108949A1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| IL277398B2 (en) | Pd-l1 binding affimers, and uses related thereto | |
| AU2019404285B2 (en) | Multimeric T-cell modulatory polypeptides and methods of use thereof | |
| CN114423284A (zh) | T细胞调节多肽及其使用方法 | |
| CA3109139A1 (en) | Methods of treating aging-related disorders | |
| JP2015524799A5 (https=) | ||
| TW201930337A (zh) | 多聚體ｔ細胞調節多肽及其使用方法 | |
| JP2020511143A5 (https=) | ||
| CN105026424A (zh) | 稳定形式的信号转化蛋白融合蛋白、及其使用和制备的方法 | |
| JP2018525006A5 (https=) | ||
| JP2025060939A5 (https=) | ||
| CA3100119A1 (en) | Fusion protein specific for cd137 and pd-l1 | |
| CN115836087A (zh) | 抗cd26蛋白及其用途 | |
| US20240376177A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| CN113286621A (zh) | 多聚体t细胞调节多肽及其使用方法 | |
| CN116981470A (zh) | T细胞调节多肽和其使用方法 | |
| JPWO2021055594A5 (https=) | ||
| JPWO2020113141A5 (https=) | ||
| KR20240024858A (ko) | sPD-1과 IL-15를 갖는 이중특이적 Fc 융합 단백질 | |
| JPWO2022161355A5 (https=) | ||
| JP2023538902A (ja) | 操作されたリガンドを使用する材料及び方法 |